Catalyst Pharmaceuticals (NASDAQ:CPRX) Coverage Initiated by Analysts at Robert W. Baird

Robert W. Baird began coverage on shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) in a report released on Tuesday morning, MarketBeat Ratings reports. The brokerage issued an outperform rating and a $28.00 target price on the biopharmaceutical company’s stock.

CPRX has been the subject of a number of other research reports. Stephens started coverage on Catalyst Pharmaceuticals in a report on Monday, November 18th. They set an “overweight” rating and a $35.00 price target for the company. Bank of America reissued a “buy” rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. StockNews.com cut Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 11th. Truist Financial boosted their price target on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a report on Monday, November 11th. Finally, HC Wainwright upped their target price on Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, January 10th. Nine analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $32.25.

Catalyst Pharmaceuticals Stock Performance

Catalyst Pharmaceuticals stock opened at $23.09 on Tuesday. Catalyst Pharmaceuticals has a 52 week low of $13.12 and a 52 week high of $24.64. The stock has a market capitalization of $2.75 billion, a P/E ratio of 19.57, a price-to-earnings-growth ratio of 2.25 and a beta of 0.80. The stock has a fifty day moving average of $22.03 and a 200-day moving average of $20.83.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, Director Molly Harper sold 17,500 shares of the company’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total value of $385,000.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Steve Miller sold 50,000 shares of the company’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total value of $1,096,500.00. Following the sale, the insider now owns 686,996 shares in the company, valued at approximately $15,065,822.28. The trade was a 6.78 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 79,500 shares of company stock worth $1,754,140. Insiders own 11.00% of the company’s stock.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. boosted its position in shares of Catalyst Pharmaceuticals by 9.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 408,261 shares of the biopharmaceutical company’s stock valued at $8,116,000 after purchasing an additional 33,888 shares in the last quarter. Wellington Management Group LLP bought a new stake in shares of Catalyst Pharmaceuticals during the 3rd quarter valued at about $1,185,000. Redhawk Wealth Advisors Inc. bought a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter valued at about $1,273,000. GSA Capital Partners LLP bought a new stake in shares of Catalyst Pharmaceuticals during the 3rd quarter valued at about $625,000. Finally, Capstone Investment Advisors LLC bought a new stake in shares of Catalyst Pharmaceuticals during the 3rd quarter valued at about $708,000. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.